Paul Bunn, MD, University of Colorado Cancer Center

home / authors / paul-bunn,-md,-university-of-colorado-cancer-center

Articles

Reducing the Impact of Chemotherapy-Induced Myelosuppression

Reducing the Impact of Chemotherapy-Induced Myelosuppression

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020

Read More

CDK4/6 Inhibitors & Myelopreservation in Other Cancers

CDK4/6 Inhibitors & Myelopreservation in Other Cancers

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020

Read More

CDK4/6 Inhibitors for SCLC: Trials of Interest

CDK4/6 Inhibitors for SCLC: Trials of Interest

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020

Read More

Chemotherapy-Induced Myelosuppression in SCLC: CDK4/6 Inhibition

Chemotherapy-Induced Myelosuppression in SCLC: CDK4/6 Inhibition

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020

Read More

Analyses of CDK4/6 Inhibitors for Myelopreservation

Analyses of CDK4/6 Inhibitors for Myelopreservation

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020

Read More

CDK4/6 Inhibitors and Myelopreservation

CDK4/6 Inhibitors and Myelopreservation

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020

Read More

Chemotherapy-Induced Myelosuppression & COVID-19

Chemotherapy-Induced Myelosuppression & COVID-19

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020

Read More

Management of Chemo-Induced Myelosuppression

Management of Chemo-Induced Myelosuppression

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020

Read More

Chemotherapy Use & Chemotherapy-Induced Myelosuppression

Chemotherapy Use & Chemotherapy-Induced Myelosuppression

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020

Read More

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

Development of KRAS G12C-Targeted Therapy in NSCLC

Development of KRAS G12C-Targeted Therapy in NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

Systemic Therapy for KRAS+ Advanced NSCLC

Systemic Therapy for KRAS+ Advanced NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

Counseling Patients With NSCLC When KRAS is Detected

Counseling Patients With NSCLC When KRAS is Detected

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

Testing for KRAS Mutations in NSCLC

Testing for KRAS Mutations in NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

KRAS Mutations in Solid Tumors

KRAS Mutations in Solid Tumors

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

Current Management of Oncogene-Driven NSCLC

Current Management of Oncogene-Driven NSCLC

Paul Bunn, MD, University of Colorado Cancer Center;Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center;Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
August 3rd 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need